Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 15/20 | 0.73 |
| ▸ | CACNB1 | Q02641 | 15/20 | 0.73 |
| ▸ | CACNA1B | Q00975 | 14/20 | 0.73 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.73 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.63 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5076791 | 0.89 | CACNA2D1 (0.75) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL26330969 | 0.87 | CACNA2D1 (0.81) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL19002255 | 0.86 | ALDH1A1 (0.74) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL3860589 | 0.85 | CACNA2D1 (0.69) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| Z160 SCHEMBL4180792 | 0.84 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL3871224 | 0.84 | CACNA2D1 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL8268615 | 0.83 | CACNA2D1 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL27571753 | 0.82 | CYP2D6 (0.71) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL19049380 | 0.81 | KMT2A (0.73) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5265406 | 0.80 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CACNA2D1 36/4885CACNB1 13/4885CACNA1B 1/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | CACNA2D1 90/4885CACNB1 4/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.